[go: up one dir, main page]

WO2000078795A3 - Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1) - Google Patents

Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1) Download PDF

Info

Publication number
WO2000078795A3
WO2000078795A3 PCT/US2000/015020 US0015020W WO0078795A3 WO 2000078795 A3 WO2000078795 A3 WO 2000078795A3 US 0015020 W US0015020 W US 0015020W WO 0078795 A3 WO0078795 A3 WO 0078795A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
useful
inhibitors
rufomycins
mrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/015020
Other languages
English (en)
Other versions
WO2000078795A2 (fr
Inventor
Palaniappan Kulanthaivel
Venkatraghavan Vasudevan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU60473/00A priority Critical patent/AU6047300A/en
Priority to EP00946770A priority patent/EP1192178A2/fr
Publication of WO2000078795A2 publication Critical patent/WO2000078795A2/fr
Publication of WO2000078795A3 publication Critical patent/WO2000078795A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des facteurs de la rufomycine et leurs dérivés utiles comme inhibiteurs de la protéine résistant aux antibiotiques. Ces composés sont utilisés, à ce titre, dans une thérapie combinatoire pour le traitement de maladies résistant aux antibiotiques. L'invention concerne aussi de nouveaux facteurs de rufomycine et leurs dérivés ainsi que leurs compositions pharmaceutiques.
PCT/US2000/015020 1999-06-21 2000-06-08 Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1) Ceased WO2000078795A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU60473/00A AU6047300A (en) 1999-06-21 2000-06-08 Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistanceassociated protein-1 (mrp-1)
EP00946770A EP1192178A2 (fr) 1999-06-21 2000-06-08 Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14036299P 1999-06-21 1999-06-21
US60/140,362 1999-06-21

Publications (2)

Publication Number Publication Date
WO2000078795A2 WO2000078795A2 (fr) 2000-12-28
WO2000078795A3 true WO2000078795A3 (fr) 2001-07-05

Family

ID=22490896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015020 Ceased WO2000078795A2 (fr) 1999-06-21 2000-06-08 Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1)

Country Status (4)

Country Link
EP (1) EP1192178A2 (fr)
AU (1) AU6047300A (fr)
PE (1) PE20010305A1 (fr)
WO (1) WO2000078795A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
BR112013000414A2 (pt) 2010-07-07 2016-05-17 Univ Texas compostos proneurogênicos
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Produits chimiques neuroprotecteurs et leurs procédés d'identification et d'utilisation
CN106279370B (zh) * 2016-09-06 2019-09-27 中国科学院南海海洋研究所 一种海洋链霉菌、及其环肽化合物在制备抗结核分枝杆菌药物中的应用
CN106397544B (zh) * 2016-09-06 2019-09-27 中国科学院南海海洋研究所 环肽类化合物在制备抗肿瘤药物中的应用
CN106497827B (zh) * 2016-10-09 2019-08-02 中国科学院南海海洋研究所 一种定向生产抗结核活性和抗肿瘤活性化合物的基因工程菌株及其应用
CN111303247B (zh) * 2019-11-21 2022-03-22 中国科学院南海海洋研究所 海洋环肽化合物及其在制备抗结核分枝杆菌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655879A (en) * 1960-02-08 1972-04-11 Takeda Chemical Industries Ltd Rufomycin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655879A (en) * 1960-02-08 1972-04-11 Takeda Chemical Industries Ltd Rufomycin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUJINO M. ET AL.: "Tryptophan Moiety of Rufomycin Homologs", CHEM.PHARM.BULL., vol. 12, no. 11, 1964, pages 1390 - 2, XP000945345 *
M.FOERTIER- BEAILIEU: "Y-A-T-IL des modalités de Surveillance Particulières Imposées par Certaines Thérapeutiques du Mélanome de Stade I?", ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, vol. 122, no. 5, 1995, pages 372 - 7, XP000945244 *

Also Published As

Publication number Publication date
PE20010305A1 (es) 2001-03-12
WO2000078795A2 (fr) 2000-12-28
AU6047300A (en) 2001-01-09
EP1192178A2 (fr) 2002-04-03

Similar Documents

Publication Publication Date Title
EE05585B1 (et) Indasoolihendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ning nende kasutamine
AU687909B2 (en) Protein kinase C inhibitors
WO2002089738A3 (fr) Composes proteomimetiques et procedes correspondants
CA2216535A1 (fr) Inhibiteurs de proteine kinase c
SE9902987D0 (sv) Novel compounds
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
CA2237221A1 (fr) Inhibiteur de la proteine kinase c
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
CA2359510A1 (fr) Diphenylurees a substituants .omega.-carboxyaryles, inhibitrices de kinase raf
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2000078795A3 (fr) Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1)
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
CA2171446A1 (fr) Antagonistes du recepteur de la bradykinine pseudo-peptidique et non peptidique
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
WO2001087287A3 (fr) Composes actifs sur le plan pharmaceutiques et procedes d'utilisation
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
WO2003051838A3 (fr) Inhibiteurs de la proteine kinase
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09979486

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000946770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000946770

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000946770

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP